OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive
Stirling, UK-Scotia became the first public UK biotechnology company to seek protection from creditors after the European Medicines Evaluation Agency rejected Foscan (temoporfin), the anticancer agent on which its fortunes were pinned.